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ABSTRACT 
There is a need for a reliable rapid on-site oral fluid test that can be used in police controls to 
detect impaired drivers.  
We evaluated the Varian Oralab®6 and collected two oral fluid samples from 250 subjects, 
one with the Varian Oralab®6 and one with the StatSure™ Saliva•Sampler™.  
The Oralab®6 can detect six drug types: amphetamines, methamphetamine, cocaine, 
opiates, delta9-tetrahydrocannabinol (THC) and phencyclidine (PCP). On-site results were 
obtained within 10 to 15 minutes. The sample collected with StatSure™ was analysed using 
Liquid Chromatography – tandem mass spectrometry after liquid-liquid extraction and these 
results were used as a reference to determine prevalence, sensitivity and specificity.  
Two cut-off values were used in the evaluation. The Varian cut-off values were: 
amphetamine 50 ng/mL, cocaine 20 ng/mL, opiates 40 ng/mL and THC 50 ng/mL. The 
DRUID cut-offs were: amphetamine 25 ng/mL, cocaine 20 ng/mL, opiates 20 ng/mL and THC 
1 ng/mL. Applying the first cut-offs, prevalence, sensitivity and specificity were: 
amphetamine: 10%, 76%, 100%; cocaine 23%, 34%, 100%; opiates 38%, 83%, 94% and 
THC 18%, 41%, 99%. The DRUID cut-off values gave the following results: amphetamine: 
14%, 56%, 100%; cocaine 28%, 34%, 100%; opiates 49%, 68%, 98% and THC 45%, 16%, 
99%. 
The specificity of the Oralab®6 is generally good. For both cut-offs, sensitivity was low for 
cocaine and THC. Therefore, the Varian Oralab®6 test is not sensitive enough to be applied 
during roadside police controls.  
 
Keywords: saliva – point of care test - Varian Oralab®6 – sensitivity 
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Introduction 
 
Oral fluid is known as a suitable matrix for the detection of drugs [1]. The presence of several 
drugs in oral fluid correlates relatively well with impairment and it has several advantages 
compared to the use of urine or blood for the detection of drugs [2]. These characteristics led 
to the search for a rapid on-site oral fluid test that can be used in police controls to detect 
impaired drivers. In Belgium, France and Australia, legislation permits use of such oral fluid 
tests during police controls [3].  
In several studies different oral fluid tests have been evaluated, mostly with disappointing 
results. The Roadside Testing Assessment-2 project (Rosita-2) evaluated nine rapid on-site 
oral fluid tests analytically, among which the previous Varian OraLab, from 2003 till 2005. 
None of these tests were found to be sensitive enough to be used on a large scale [4]. Later 
evaluation of several other tests, for example the Dräger DrugTest® [5], the Cozart® 
RapiScan System [6] and the Drugwipe 5 [7], could not show significant improvement.     
The aim of this study was to determine the reliability of the On-site® Varian OraLab®6 
(Varian Inc., Lake Forest, California, USA) for detection of drugs of abuse. Therefore, 
sensitivity and specificity were determined based on the results of 250 collected oral fluid 
samples with the Oralab®6, compared to the results of a second oral fluid sample obtained 
as reference, analysed with ultra pressure liquid chromatography – tandem mass 
spectrometry (UPLC-MS/MS).  
This study was conducted within a project financed by the European Commission, ‘Driving 
Under the Influence of Drugs, Alcohol and Medicines’ (DRUID). This project was set up to 
investigate the influence of psychoactive substances – drugs, alcohol and medicines – on 
traffic safety. Within the work package ‘enforcement’, several on-site oral fluid tests, among 
which the Varian Oralab, are evaluated, from an operational and analytical perspective [8].   
 
Method and materials 
Samples 
 
Oral fluid samples were collected from 250 subjects. Two hundred were obtained in a 
rehabilitation centre for drug addicts, the other 50 subjects were selected during roadside 
surveys. Two oral fluid samples were collected, one with the Varian Oralab®6, and the other 
with the StatSure™ Saliva•Sampler™ (StatSure™, Brooklyn, NY, USA), an oral fluid 
collector. 
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Varian OraLab instrument 
 
The Oralab®6 test consists of 3 elements: an oral fluid collector, the test tube and the test 
card, as shown in Figure 1. The oral fluid collector is a swab with a salty taste (to increase 
saliva production), the test tube contains the oral fluid when it is squeezed out of the swab 
and it is shaped to hold the test card. The test card is the actual lateral-flow immunoassay to 
detect drugs in the oral fluid.  
Since this study, the Varian Oralab®6+ has been introduced, it differs in design compared to 
the Varian Oralab®6, but the immunoassay itself is still the same. 
 
Figure 1: The Varian Oralab®6 on-site fluid test, consisting of an oral fluid collector, the test 
tube and the test card (inside the tube) 
 
Oral Fluid Collector 
The oral fluid for the sample with the Oralab®6 was collected by keeping the swab under the 
tongue for about three minutes, which normally was sufficient to collect a minimum of 1mL 
oral fluid and proceed with the test.  
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Test tube 
After collection of the oral fluid with the swab, the latter was squeezed out in the test tube. 
The test card was inserted in the tube to perform the test and removed within 15 minutes to 
read the results. The test tube with the remaining oral fluid was stored in the freezer for later 
analysis. 
 
Test card 
The Oralab®6 detects amphetamine (AMP), methamphetamine (METH), opiates (OPI), 
cocaine (COC), delta9-tetrahydrocannabinol (THC) and phencyclidine (PCP). The test card 
is a qualitative immunoassay, based on competitive inhibition. For each of the six tested 
drugs, immobilized drug conjugates and red-labeled antibody-coated micro particles are 
attached to a membrane. By introducing the test card into the tube, the membrane of the test 
card absorbs the oral fluid. The drugs in the sample compete with and exceed the drug 
conjugates for interaction with the antibody coated micro particles, which results in a clean 
line next to the first character of the corresponding drug name. Absence of drugs in the 
sample results in a red line. There are also two control lines to ensure the oral fluid was 
sufficiently migrated by the test card.  
Fig. 2 shows a test card that is positive for opiates and negative for the other drugs.  
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Figure 2: A Varian Oralab®6 test card, positive for opiates (no line) negative for the other 
drugs. TV: test valid, A: amphetamine, O: opiates, C: cocaine, P: phencyclidine, M: 
methamphetamine, T: cannabinoids 
StatSure™ Saliva•Sampler™ 
 
Since there is no buffer in the test tube of the Varian Oralab®6, a good conservation of the 
drugs, particularly THC, during storage is not guaranteed. There is a risk of drugs adhering to 
the oral fluid collector or to the test tube. Therefore, a second saliva sample was collected 
with the StatSure™ Saliva•Sampler™. This is an oral fluid collector with good recovery and 
stability of drugs in the oral fluid during storage [9]. The concentrations of drugs found in this 
second sample after analysis with LC-MS/MS were adjusted for volume, based on the weight 
of the StatSure™ device after collection.  
Fig. 3 shows the StatSure™ Saliva•Sampler™, which consists of two elements: an oral fluid 
collector and a transport tube.  
 
 
Figure 3: The StatSure™ Saliva•Sampler™, consisting of an oral fluid collector and a 
transport tube 
 
Oral fluid collector 
The StatSure™ oral fluid collector is also a swab that has to be kept under the tongue to 
absorb saliva. In this case, there is an indicator in the plastic handle that turns blue when 1 
mL oral fluid is collected. 
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Transport tube 
The transport tube contains 1 mL of buffer that dilutes the saliva sample and results in a 
good conservation of the drugs in the sample. The transport tube was stored in the freezer 
for later analysis with LC-MS/MS. 
Standards and reagents 
All chemicals and solvents used were analytical or HPLC grade. Ammonium acetate was 
obtained from Fluka (Bornem, Belgium), Heptane was purchased from Sigma-Aldrich 
(Bornem, Belgium), ethyl acetate and methanol from Biosolve (Valkenswaard, The 
Netherlands). Water was purified by an Elga Medica R 7 system from Rossmark (Ede, The 
Netherlands). All standards and deuterated internal standards were purchased from LGC 
Promochem (Molsheim France). 
 
Confirmation analysis 
Liquid-liquid extraction 
The StatSure™ sample was prepared with liquid-liquid extraction before analysis. From the 
sample, 400 µL was used. Twenty µL of a 20 ng/mL solution of isotope-labeled internal 
standards was added. Two hundred µL ammonium bicarbonate (0.2 M, pH 9.3) and 1.25 mL 
heptane/ethyl acetate (1:4) were added. This mixture was vortexed (5 seconds), shaken (15 
minutes) and centrifuged (3000 rpm; 5 minutes). The organic phase was removed and 
evaporated at room temperature. After addition of 100 µL H2O/methanol (50:50), vortexing (5 
seconds) and centrifuging (2 minutes), the sample was transferred to a vial for analysis with 
UPLC-MS/MS. 
 
Ultra performance liquid chromatography  
The AcquityTM Ultra Performance liquid chromatograph (Waters, Zellik, Belgium) was 
equipped with an Acquity UPLC ® BEH C18 column (1.7 µm; 2.1 x 50 mm), and a Vanguard 
BEH C18 precolumn (1.7 µm; 2.1 x 5 mm).  
As mobile phase a gradient elution of H2O with 2 mM NH4HCO3, pH 9.30 (mobile phase A) 
and LC-MS methanol (mobile phase B) was applied, as shown in figure 4. The temperature 
of the column was 60°C, the temperature of the sample manager 10°C and the injection 
volume was 25 µL. 
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Figure 4: Gradient elution as mobile phase, with mobile phase A (H2O with 2mM NH4CO3) 
and mobile phase B (methanol) 
 
Tandem mass spectrometry 
A Quattro PremierTM XE (Waters) was used, with an Electrospray Ionization-source in 
positive mode.  
The general characteristics of the tandem mass spectrometry are shown in table 1. The 
different components that were measured and some of their corresponding parameters are 
summarized in table 2. 
Imprecision and inaccuracy were lower than 15% for all analytes at the DRUID cut-offs, 
demonstrating that the limit of quantitation (LOQ) of the method was lower than required by 
the DRUID consortium. 
The regression model was quadratic for all components, except for THC, for which the model 
was linear. The regression model fitted for all analytes within the 0.5-200 ng/mL calibration 
range (r²>0.99 for all analytes, except for benzoylecgonine: 0.98). And although absolute 
matrix effects were observed with some analytes, the relative matrix effect (measured using 
the coefficient of variation of slopes of standard lines from five different sources) was lower 
than 2% and hence it can be assumed that the absolute matrix effects observed did not 
affect the quantification of analytes (Table 3). 
Table 1: General parameters for mass spectrometry 
 Parameter Value 
ES+ 
Source 
Capillary Voltage 0.8 kV 
 Extractor Voltage 4 V 
C
on
ce
nt
ra
tio
n 
(%
) 
Time (min.) 
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 RF Lens 0 V 
 Source Temperature 140 °C 
 Desolvation Temperature 450 °C 
 Desolvation Gas Flow 1000 L/h 
 Cone Gas Flow 50 L/h 
Analyser Collision Gas Flow 0.15 
mLmL/min 
 
 
Table 2: Measured components with the corresponding parameters  
Component Q 1 Q 3 Dwell time 
(sec) 
Retention 
time (min) 
Cone 
(Volt) 
Collision 
Energy (eV) 
6-acetylmorphine 328.12 152.08 0.035 3.61 47 61 
6-acetylmorphine-D3 331.10 164.90 0.035 3.58 45 37 
Amphetamine 136.07 119.05 0.035 3.43 15 9 
Amphetamine-D5 141.01 92.90 0.035 3.37 17 27 
Benzoylecgonine 290.14 168.00 0.035 2.64 33 19 
Benzoylecgonine-D3 293.10 171.00 0.035 2.65 33 19 
Cocaine 304.11 182.1 0.015 4.66 31 19 
Cocaine-D3 307.10 185.00 0.015 4.64 31 19 
Codeine 300.14 165.01 0.030 3.85 41 43 
Codeine-D3 303.10 215.00 0.030 3.83 45 25 
MDA 180.02 105.03 0.035 3.28 15 21 
MDA-D5 185.01 110.00 0.035 3.23 17 21 
MDEA 208.10 162.97 0.030 3.79 23 13 
MDEA-D5 213.07 162.90 0.030 3.69 21 13 
MDMA 194.10 162.95 0.035 3.43 21 13 
MDMA-D5 199.10 135.20 0.035 3.34 21 21 
Methamphetamine 149.96 90.95 0.030 3.61 21 17 
Methamphetamine-D5 155.00 120.90 0.030 3.55 19 11 
Morphine 286.11 152.10 0.035 3.13 45 53 
Morphine-D3 289.08 164.90 0.035 3.10 43 37 
THC 315.18 193.05 0.060 5.44 31 21 
THC-D3 318.13 196.00 0.020 5.43 31 25 
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Table 3: validation parameters for the different analytes in the UPLC-MS/MS method. 
Component R2 Imprecision 
(%)^ 
Inaccuracy 
(%)^ 
DRUID 
cut-off 
(ng/mL) 
Extraction 
yield* (%) 
LOQ 
(ng/mL) 
Absolute 
matrix 
effect 
(%)£ 
Relative 
matrix 
effect 
(CV)$ 
6-acetylmorphine 0.999 13.6 -3.6 5.0 75.1 5.0 -11.5 1.8 
Amphetamine 0.993 6.8 +6.2 25 54.8 10.6 16.2 2.0 
Benzoylecgonine 0.983 3.4 +2.4 10 2.8 5.5 8.7 1.8 
Cocaine 0.999 8.4 -2.2 10 78.3 6.4 3.1 1.0 
Codeine 0.999 7.0 -0.8 20 70.4 0.5 19.7 1.6 
MDA 0.998 7.7 +1.5 25 58.1 16.7 1.3 1.8 
MDEA 0.997 10.4 -3.5 25 70.3 0.5 11.5 1.7 
MDMA 0.997 9.6 +1.8 25 65.9 0.5 4.2 1.5 
Methamphetamine 0.997 6.6 +0.4 25 56.5 0.5 6.6 1.4 
Morphine 0.997 8.3 +0.5 20 39.5 0.5 6.0 1.1 
THC 0.998 8.8 -3.9 1.0 52.6 1.0 93.5 1.1 
^ imprecision and inaccuracy determined at DRUID cut-offs [8]; * extraction yield determined at 20 ng/mL;  
£ absolute matrix effect determined at 100 ng/mL; $ CV of slopes of standard lines from five different sources 
Cut-off values 
 
The cut-off values stated by Varian for the OraLab are 50 ng/mL amphetamine, 50 ng/mL 
methamphetamine, 20 ng/mL cocaine, 40 ng/mL opiates, 50 ng/mL THC and 10 ng/mL PCP. 
However, within the Driving Under the Influence of Drugs-project (DRUID) other confirmation 
cut-off values are determined. These cut-off values are 25 ng/mL amphetamine, 25 ng/mL 
methamphetamine, 20 ng/mL cocaine, 20 ng/mL opiates and 1 ng/mL THC. For PCP no cut-
off value was determined, since this drug is very rarely used in Europe.  
The recommended cut-off values as mentioned in Guidelines for research on drugged driving 
[10] are 20 ng/mL for amphetamine and methamphetamine, 10 ng/mL for cocaine, 20 ng/mL 
for codeine and morphine, 5 ng/mL for 6-acetylmorphine and 2 ng/mL for THC. The DRUID 
cut-offs are less sensitive for amphetamine, methamphetamine, cocaine and 6-
acetylmorphine, but more sensitive for THC.  
 
Cross reactivity 
 
In order to compare the UPLC-MSMS concentrations with the Varian cut-offs, the 
concentrations were added, taking the cross-reactivity of the OraLab-6 into consideration:  
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COC+BE = conc(COC) + 0.067 * conc(BE) 
OPI = conc(MORPH) + 1.4 * conc(6-AM) + 1.4 * conc(COD) 
 
Results 
Drugs found by UPLC-MS/MS 
Table 4 describes the analytical results for the different drugs. Often, very high 
concentrations were found, suggesting recent drug use. 
Table 4: UPLC-MS/MS results for the individual drugs: number of positive samples, lowest, 
median and highest concentrations observed in the samples where the drug was detected. 
MDA, MDEA, MDMA and methamphetamine were not observed.  
Component n Lowest  
Concentration  
(ng/mL) 
Median 
Concentration  
(ng/mL) 
Highest 
Concentration 
(ng/mL) 
6-acetylmorphine 109 5.4 75.4 9787 
Amphetamine 33 25.0 685.1 21153 
Benzoylecgonine 48 10.9 81.5 14155 
Cocaine 54 10.3 52.2 20632 
Codeine 71 20.1 60.7 742 
Morphine 97 20.6 186.7 9159 
THC 112 1.0 31.4 3967 
 
Prevalence, sensitivity, specificity and accuracy 
The reliability of the Oralab®6 compared to the results of the StatSure™ sample is given in 
Table 5. There were no positive results for methamphetamine and PCP gave 5 false positive 
results with the on-site test. 
Table 5: Prevalence, sensitivity, specificity and accuracy of Oralab®6 for DRUID and Varian 
cut-off values 
 DRUID Cut-off  Varian Cut-off* 
 
Prev 
(%) 
Sens 
(%) 
Spec 
(%) 
Acc 
(%) 
 Prev 
(%) 
Sens 
(%) 
Spec 
(%) 
Acc 
(%) 
COC+BE 22.5 33.9 100 85.1  17.2 37.2 98.5 87.9 
OPI 45.0 75.0 97.8 87.6  40.9 82.3 97.9 91.5 
THC 44.9 16.0 98.5 61.4  17.6 40.9 99.0 88.7 
AMP 13.2 55.6 100 94.3  10.0 76.0 100 97.5  
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            *adjusted for cross-reactivity: COC+BE=COC+0.067 x BE; OPI=MORPH+1.4 x 6-AM+1.4 x COD 
 
To determine the reliability of the Varian Oralab®6, the DRUID cut-off values must be used. 
The results with the Varian cut-off values, which are higher, were used to determine if the 
manufacturer could meet up to their own standards.  
Applying the DRUID cut-offs, specificity was high for all drugs. Sensitivity was relatively high 
for opiates, medium for amphetamines and cocaine, and very low for THC. Comparing these 
results to the ones achieved with the Varian cut-off values, the latter give generally better 
results, due to the higher detection limits. The biggest differences are seen for THC, but the 
cut-off values between Varian and DRUID differ 50-fold (respectively 50 ng/mL and 1 ng/mL). 
In figures 5 to 8, the log of the StatSure™ concentrations was plotted against the test card 
results and presented as box-and-whisker plots. The outliers are represented by circles, the 
extreme outlier by a triangle.  
For all drugs, there was a wide spread of drug concentrations that yielded a negative test 
card result. Moreover, there is an overlap between the negative and positive test card results 
for THC, cocaine and opiates, which means there was no clear distinction in the 
concentrations that give a negative result with the oral fluid test and those with a positive 
result. Only for amphetamine there was a clear distinction, except for the outliers.  
	  	  	  	  	  	  	  	  
 
Figure 5: Box-and-whisker plot for THC: StatSure™ concentrations (log) according to test 
card result (0 = negative, 1 = positive); compared to the Varian cut-off (50 ng/mL) and the 
DRUID cut-off (1 ng/mL) 
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Figure 6: Box-and-whisker plot for amphetamines: StatSure™ concentrations (log) according 
to test card result (0 = negative, 1 = positive); compared to the Varian cut-off (50 ng/mL) and 
the DRUID cut-off (25 ng/mL) 
 
  
       
Figure 7: Box-and-whisker plot for opiates (6-acetylmorphine + codeine + morphine): 
StatSure™ concentrations (log) according to test card result (0 = negative, 1 = positive); 
compared to the Varian cut-off (40 ng/mL) and the DRUID cut-off (20 ng/mL) 
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Figure 8: Box-and-whisker plot Cocaine + Benzoylecgonine: StatSure™ concentrations (log) 
according to test card result (0 = negative, 1 = positive); compared to the Varian and DRUID 
cut-off (both 20 ng/mL) 
 
Positive and Negative Predictive value 
 
The positive and negative predictive values (PPV and NPV) can indicate whether a test is 
also applicable in other populations than in the one selected for the study. PPV and NPV are 
prevalence-dependent, this relation is reflected in the theorem of Bayes and it is important to 
keep in mind when applying these values on other populations.  
In this case it is important to apply the results from the study to traffic settings and police 
controls, where prevalence values are low.    
PPV and NPV were calculated for prevalence from 0% till 100% and are displayed per drug 
type in figures 9 and 10. PPV was 1 for each prevalence value in the case of cocaine and 
amphetamine, due to a specificity of 100% for those drugs; therefore it is not represented in 
figure 9.   
In traffic, the normal prevalence of drug use is approximately 1%, this gives a PPV of 25% for 
opiates and 10% for THC, NPV is 99% for all drugs. 
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OPI = opiates (morphine, codeine and 6-acetylmorphine); THC= delta9-tetrahydrocannabinol 
Figure 9: Positive predictive value plotted against prevalence. 
 
 
COC+BE= cocaine + benzoylecgonine; OPI= opiates (morphine, codeine, 6-acetylmorphine); THC= delta9-
tetrahydrocannabinol; AMP= amphetamine 
Figure 10: Negative predictive value plotted against prevalence. 
 
Discussion 
 
The prevalence in this study is not the prevalence seen in a traffic setting, since 80% of the 
study subjects were recruited in a drug rehabilitation centre and only 20% in a normal traffic 
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setting. Within the 200 study subjects recruited in the drug rehabilitation centre, 85% tested 
positive with UPLC-MS/MS for one or more drug types. The normal prevalence of drug use in 
traffic is approximately 1%. 
Looking at the prevalence for each drug separately, we see THC and opiates have the 
highest percentages (~45%) with the DRUID cut-offs. Cannabis is a widely used drug and 
earlier research showed that THC is the most prevalent drug among impaired drivers in 
Belgium, followed by amphetamine and ecstasy [11]. In this study opiates follow THC 
regarding prevalence, but this was also as expected, since the majority of the recruited drug 
addicts come to the rehabilitation centre for methadone substitution, to control their heroin 
addiction.   
The 50-fold higher Varian cut-off for THC (50 ng/mL) results in a much lower prevalence 
(only 17%), which indicates that 28% of the THC concentrations were between 1 and 50 
ng/mL. 
 
Figures 5 to 8 illustrate that the lowest detectable concentration with the Varian Oralab®6 
test card is higher than the one mentioned by the manufacturer. Even with the higher Varian 
cut-off values, the test card is not sensitive enough for cocaine and THC.  
Comparing the results of this study with the results obtained with the Varian OraLab tested 
during the Rosita-2 project, there are some significant differences. While the OraLab faced a 
failure percentage of more than 25%, and many officers lost their enthusiasm to continue 
recruiting subjects, there were no such problems during the study with the Varian Oralab®6. 
At the other hand, the sensitivity in the present study is lower than in the Rosita-2 evaluation 
(table 6). This is probably explained by the fact that in Rosita-2 the negative screening 
results with OraLab were not systematically confirmed, which resulted in an overestimation of 
the sensitivity. 
The sensitivity of the Oralab®6 is also lower than most other tests of Rosita-2. Specificity and 
accuracy was in general better than seen in those other tests. But the threshold for a 
sensitive test was 90%, so anyhow, further research on and improvement of the test card of 
the Varian Oralab®6, definitely for cocaine and THC, is absolutely necessary. 
Table 6: Prevalence, sensitivity, specificity and accuracy of the Varian OraLab, tested during 
the Rosita-2 project [4]. 
 Prev 
(%) 
Sens 
(%) 
Spec 
(%) 
Acc 
(%) 
COC+BE 19.3 97.2 96.7 96.8 
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OPI 3.7 100.0 100.0 100.0 
THC 13.5 73.9 99.3 95.9 
AMP 1.6 66.7 98.4 97.9 
 
Walsh et al. [12] also tested if the cut-off concentrations postulated by the manufacturer were 
achieved. For most tests, false negatives and false positives were detected for each drug 
type. The OraLab gave false negatives for opiates and THC and false positives for cocaine. 
Looking at the results of the Oralab®6 in this study, there are false negatives for each drug 
type and for all, except for amphetamine, false positives.  
 
Conclusion 
 
The aim of this study was to evaluate the reliability of the Varian Oralab®6 to determine 
whether this rapid on-site oral fluid test can be used for drug detection during police controls. 
Applying the DRUID cut-off values, the sensitivity of the test is too low, especially for cocaine 
(35%) and THC (16%). Specificity was high for all drugs (98-100%).  
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